A large coalition of medical associations, patient advocacy groups, drug companies, and others sent a letter to Congress Monday asking that they intervene on a CMS plan to use an index based on drug prices in other countries to determine reimbursement for Part B therapies, saying it would have a negative effect on the elderly and people with disabilities.